Pharming Group N.V (PHAR) Research & Development: 2020-2025
Historic Research & Development for Pharming Group N.V (PHAR) over the last 4 years, with Jun 2025 value amounting to -$44.8 million.
- Pharming Group N.V's Research & Development fell 11.76% to -$44.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $38.3 million, marking a year-over-year decrease of 18.16%. This contributed to the annual value of $83.1 million for FY2024, which is 20.65% up from last year.
- Pharming Group N.V's Research & Development amounted to -$44.8 million in Q2 2025, which was down 131.14% from $144.0 million recorded in Q4 2024.
- Pharming Group N.V's 5-year Research & Development high stood at $144.0 million for Q4 2024, and its period low was -$44.8 million during Q2 2025.
- Over the past 3 years, Pharming Group N.V's median Research & Development value was -$20.7 million (recorded in 2024), while the average stood at $8.1 million.
- As far as peak fluctuations go, Pharming Group N.V's Research & Development skyrocketed by 363.16% in 2021, and later plummeted by 138,806.54% in 2022.
- Quarterly analysis of 5 years shows Pharming Group N.V's Research & Development stood at $70.4 million in 2021, then soared by 33.69% to $94.2 million in 2022, then skyrocketed by 34.01% to $126.2 million in 2023, then rose by 14.09% to $144.0 million in 2024, then dropped by 11.76% to -$44.8 million in 2025.
- Its last three reported values are -$44.8 million in Q2 2025, $144.0 million for Q4 2024, and -$20.7 million during Q3 2024.